Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
14Dec2025
  • Home
  • About
  • News
  • Subscribe
14Dec2025
Cost Curve NewsCost Curve News
Cost Curve News

No One Had Dr. Oz on Their Bingo Card

I’m now over at Bluesky as @brianreid.bsky.social. I really don’t need another social account to tend to, so most of my posting will remain at LinkedIn. But the community at
1 year ago
Keep Reading
Cost Curve News

How to Think and Talk About Value in the RFK Jr. Era, Part Two

Minnesota 340B Watch Update. I emailed the nice folks at the Minnesota Department of Health about where their 340B transparency report, and I quickly received a brief reply: “We hope
1 year ago
Keep Reading
Cost Curve News

How to Think and Talk About Value in the RFK Jr. Era, Part One

I keep promoting a big Minnesota state report on 340B that keeps not appearing. Per statute, something was supposed to go from the state’s Minnesota Department of Health to the
1 year ago
Keep Reading
Cost Curve News

Nine Thoughts on RFK Jr.’s Nomination to Head HHS

We’re going to talk about Robert Kennedy today. Here’s the tweet announcing his nomination. Here’s reaction from PhRMA and BIO. I haven’t seen anything from the American Hospital Association or
1 year ago
Keep Reading
Cost Curve News

‘It’ll Raise Premiums’ Tends to Kill Fruitful Conversations About Benefit Design. We Can Do Better.

It’s still all mostly politics out there, with heat but no light when it comes to the topics that we’re focused on here. So most of the newsletter is deep
1 year ago
Keep Reading
Cost Curve News

Digging Into Paragon’s Policy Ideas for Hints About Where Trump 2.0 Will Go on Drug Pricing

I am not a fan of the sound of my own voice (is anyone?), but I appeared on Stacey Richter’s absolutely wonderful Relentless Health Value podcast last week. Stacey is
1 year ago
Keep Reading
Cost Curve News

J&J Hits Back on 340B as the ‘Rebate Model’ Heads to Federal Court

I warned yesterday that the news flow around pricing -- reduced to a trickle by the election attention -- was going to come flooding back one of these days.  Today
1 year ago
Keep Reading
Cost Curve News

Where Pharma Came Down on the IRA During 3Q24 Earnings Calls

The non-Trump news flow remains a trickle. That’s not going to last. Buckle up. It’s going to be an intense 44 days between now and Christmas.  And a shout-out to
1 year ago
Keep Reading
Cost Curve News

There’s a Ton of Trump Coverage. I’m Just Not Sure You Need to Pay Close Attention

The newsletter today is just this quick hello and the brief missive below. We’ll be off tomorrow.  *** It’s not that there’s nothing out there. There is a ton to
1 year ago
Keep Reading
Cost Curve News

The Presidential Election Results Might Be Clear, But the Health Policy Implications Are Not

The presidential election is all over but the shouting, as they say. You don’t subscribe to the Curve for political commentary or analysis, so I’ll spare you. If you’re looking
1 year ago
Keep Reading
252627

Latest Posts

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

December 8, 2025

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

December 5, 2025

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

December 4, 2025

Popular

A New Tracker for Watching Meds That Might See Prices Slashed

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (2,939)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,029)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (1,921)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,719)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,711)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2025 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe